Published in Gastroenterology Week, November 14th, 2005
"Tegaserod is a promotility agent with proven efficacy and safety" in such patients, according to scientists in the United States, who conducted a study "to assess tegaserod's effect on work productivity and daily activity."
"Women, 18-65 years old and meeting Rome II criteria for irritable bowel syndrome with constipation, were randomized to a double-blind, placebo-controlled, multicenter study of tegaserod 6 mg b.d. or placebo," explained M.C. Reilly and coauthors at Margaret Reilly Associates, Inc. in New York. "Productivity loss and daily activity...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.